Development of Transdermal Delivery System of Vildagliptin and Its Comparison with Oral Therapy.

Nair, Anroop B.; Kumria, Rachna; Al‐Dhubiab, Bandar E.; Attimarad, Mahesh; Harsha, Sree

doi:10.5530/ijper.50.1.17

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) and the results were reported in table 3. The release studies revealed a 2.1 times higher flux for D-2510 when compared with D-2852 [21]. The low penetration of the drug from D-2852 was due to carboxyl group interaction with the functional group present in the drug.…”

Section: In Vitro Permeation Studiesmentioning

confidence: 90%

Drug in Adhesive Transdermal System of Furosemide: In Vitro in Vivo Evaluation

YALLAMALLI,

MANNAM,

YELLAMELLI

2023

Int J App Pharm

View full text Add to dashboard Cite

Objective: The objective of the present work aims to check the effect of penetration enhancers on release kinetics in a novel drug in the adhesive transdermal system of furosemide. Methods: The adhesive systems were evaluated for pharmacotechnical properties and in vitro permeation of the drug through the excised rat epidermis. Among the DURO-TAKs screened for in vitro permeation studies. The results were quantified using RP-HPLC. The optimized drug in the adhesive system was subjected to in vivo kinetic studies using New Zealand male rabbits. The adhesive systems were further evaluated for tack properties and skin irritation studies. Results: DURO-TAK 2510 demonstrated a best permeation profile than DURO-TAK 2852. A combination of penetration enhancers was proved to more be efficient than alone, in the case of F9 (IPM: PG 7.5:2.5) maximum permeation of the drug (314.45±5.97 µg/cm2) was observed by the end of the study with a flux of 9.2052±0.33 μg/cm2/h. The optimized drug in the adhesive system was subjected to in vivo kinetic studies using New Zealand male rabbits. The studies confirmed that controlled release of the drug for a prolonged duration with an extended AUC and MRT decreased Cmax in adhesive systems compared to the oral route, which can provide a promising pharmacological effect the in the DIA system compared to the oral route. Conclusion: The findings in the present study confirmed that drugs in adhesive systems can provide promising results and can enhance both bioavailability and patient compliance with a combination of penetration enhancers in the development of DIA systems.

show abstract

Section: In Vitro Permeation Studiesmentioning

confidence: 90%

Drug in Adhesive Transdermal System of Furosemide: In Vitro in Vivo Evaluation

YALLAMALLI,

MANNAM,

YELLAMELLI

2023

Int J App Pharm

View full text Add to dashboard Cite

show abstract

“…Formulation components like adhesives, release liner, backing film, drug loading, etc., generally influences the efficacy of transdermal patches [22,32]. The physicochemical properties of adhesives, like the functional groups, can impact drug permeation.…”

Section: Screening Of Transdermal Patch Componentsmentioning

confidence: 99%

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch

et al. 2023

View full text Add to dashboard Cite

Clinical application of treprostinil in pulmonary arterial hypertension is hampered by adverse effects caused by its high dosing frequency. The objective of this investigation was to Formulate an adhesive-type transdermal patch of treprostinil and evaluate it both in vitro and in vivo. A 32-factorial design was utilized to optimize the selected independent variables (X1: drug amount, X2: enhancer concentration) on the response variables (Y1: drug release, Y2: transdermal flux). The optimized patch was evaluated for various pharmaceutical properties, skin irritation, and pharmacokinetics in rats. Optimization results signify considerable influence (p < 0.0001) of X1 on both Y1 and Y2, as compared to X2. The optimized patch possesses higher drug content (>95%), suitable surface morphology, and an absence of drug crystallization. FTIR analysis revealed compatibility of the drug with excipients, whereas DSC thermograms indicate that the drug exists as amorphous in the patch. The adhesive properties of the prepared patch confirm adequate adhesion and painless removal, while the skin irritation study confirms its safety. A steady drug release via Fickian diffusion and greater transdermal delivery (~23.26 µg/cm2/h) substantiate the potential of the optimized patch. Transdermal therapy resulted in higher treprostinil absorption (p < 0.0001) and relative bioavailability (237%) when compared to oral administration. Overall, the results indicate that the developed drug in the adhesive patch can effectively deliver treprostinil through the skin and could be a promising treatment option for pulmonary arterial hypertension.

show abstract

“…The dose was based on the body weight (mg/kg) and calculated through following formula The Methanolic crude extracts (MCE) were dissolved and diluted with distilled water. Controlled animals were treated with an equal volume of saline solution of raw pieces [17].…”

Section: Extract Dose Preparationmentioning

confidence: 99%